Lv61
2680 积分 2021-12-16 加入
Epidemiological Analysis of Psoriasis in China from 2020 to 2022
24天前
已关闭
Epidemiological Analysis of Psoriasis in China from 2020 to 2022
24天前
已完结
Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial
26天前
已完结
A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results
1个月前
已关闭
A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results
1个月前
已完结
Long‐term efficacy, safety and tolerability of secukinumab in children and adolescents with severe chronic plaque psoriasis: Two‐year results from a Phase III double‐blind, randomized controlled trial
1个月前
已完结
Long‐term efficacy, safety and tolerability of secukinumab in children and adolescents with severe chronic plaque psoriasis: Two‐year results from a Phase III double‐blind, randomized controlled trial
1个月前
已完结
The impact of accelerated drug marketing registration procedures on the review and approval of new drugs in China
1个月前
已完结
Pruritus in psoriasis: clinical characteristics, pathogenesis and treatment
3个月前
已关闭
皖公网安备34019202002308
